<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20265" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Daunorubicin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saleem</surname>
            <given-names>Tabinda</given-names>
          </name>
          <aff>UPMC Pinnacle Hospitals</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kasi</surname>
            <given-names>Anup</given-names>
          </name>
          <aff>University of Kansas</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Tabinda Saleem declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anup Kasi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>28</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20265.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Daunorubicin is an anthracycline antibiotic mainly used to treat various types of cancers, especially leukemias. It can be used to treat both acute and chronic leukemias. This activity will summarize the mechanism of action, adverse event profile, and other key factors (e.g., indications, contraindications, pharmacodynamics, pharmacokinetics, monitoring, relevant interaction) pertinent to daunorubicin therapy well as important prescribing and management consideration by the healthcare team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action and administration of daunorubicin.</p></list-item><list-item><p>Describe the potential adverse effects of daunorubicin.</p></list-item><list-item><p>Outline the appropriate monitoring necessary for patients receiving daunorubicin.</p></list-item><list-item><p>Review interprofessional team strategies for improving care coordination communication to advance daunorubicin therapy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20265&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20265">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20265.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Daunorubicin is an anti-neoplastic agent that has approval from the Food and Drug Administration (FDA) as a remission induction therapy along with another cytotoxic agent in acute non-lymphocytic leukemias including acute myelogenous, promyelocytic, and erythroid leukemias in adults and acute lymphocytic leukemia (ALL) in both children and adults.</p>
        <p>In adult non-lymphocytic leukemias, daunorubicin hydrochloride has been seen to produce a complete remission rate of 40 to 50% when used as a single agent and 53 to 65% complete remission rate when used with cytarabine. The cumulative dose of 270 mg/m^2, along with cytarabine, has been shown to be most effective with the lowest toxicity rates.<xref ref-type="bibr" rid="article-20265.r1">[1]</xref><xref ref-type="bibr" rid="article-20265.r2">[2]</xref></p>
        <p>Clinical studies showed that daunorubicin prolongs the complete remission duration of childhood ALL when used in combination with vincristine-prednisone compared to using vincristine and prednisone alone. However, no evidence is available regarding its impact as a part of consolidation therapy. Whereas in adult ALL, daunorubicin significantly increases the rate of complete remission from 47% to 83% when added to the triple therapy with vincristine, prednisone, and L asparaginase; however, it does not affect the duration of the complete remission.<xref ref-type="bibr" rid="article-20265.r3">[3]</xref></p>
        <p>Daunorubicin is also used as part of the aggressive CHOP (cyclophosphamide, daunorubicin, vincristine, and prednisone) regime to treat adult T cell leukemia caused by human T-lymphotropic virus (HTLV) and other chronic lymphomas, although the long-term remission effects are limited.<xref ref-type="bibr" rid="article-20265.r4">[4]</xref></p>
        <p>In 2017 the liposomal co-formulation of daunorubicin and cytarabine was approved by the FDA for the treatment of adults with therapy-related AML or AML with myelodysplasia-related changes (AML-MRC), these two types of AML are known for their poor prognosis.<xref ref-type="bibr" rid="article-20265.r5">[5]</xref><xref ref-type="bibr" rid="article-20265.r4">[4]</xref></p>
        <p>Off-label, the liposomal form of daunorubicin, is also used as a first-line agent to treat Kaposi sarcoma in patients with advanced human immunodeficiency virus (HIV) syndrome along with HAART therapy.<xref ref-type="bibr" rid="article-20265.r6">[6]</xref></p>
      </sec>
      <sec id="article-20265.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Daunorubicin&#x000a0;is a member of the anthracycline class of antibiotics. It exerts its anti-neoplastic properties through various mechanisms that include both anti-mitotic and anti-cytotoxic activities. It acts by intercalating between the DNA base pairs, causing the DNA double helix to uncoil and inhibit the topoisomerase II enzyme, resulting in single and double-strand breaks, thus inhibiting DNA and RNA synthesis.</p>
        <p>Daunorubicin also inhibits polymerase enzyme activity, dysregulating the gene expression and resulting in free radical damage to the DNA and ultimately resulting in apoptosis, mitochondrial injury, and programmed cell death.</p>
      </sec>
      <sec id="article-20265.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Daunorubicin can only be administered intravenously through rapidly flowing infusions. Its administration cannot be subcutaneous or intramuscular as it can cause severe local tissue necrosis through the extravasation of the drug into the surrounding tissue. In the event of extravasation, the infusion should stop immediately, and cold compresses should be applied.&#x000a0;</p>
        <p>Generalized dosing for daunorubicin is as follows:</p>
        <p>
<bold>Acute Lymphocytic Anemia (ALL)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>45 mg/m^2 IV for one dose on days 1 to 3 of each cycle. The maximum cumulative dose is 550 mg/m^2, except in cases with prior mediastinal X-ray therapy, then reduce the dose&#x000a0;to 400 mg/m^2.</p>
          </list-item>
        </list>
        <p>
<bold>Acute Myeloid Leukemia (AML)</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient less than 60 years old:&#x000a0;45 mg/m^2 IV for one dose on days 1 to&#x000a0;2&#x000a0;for 2 cycles. Starting with the third cycle dose&#x000a0;45 mg/m^2 IV for one dose on days 1 to 3 of each cycle. The maximum cumulative dose is 550 mg/m^2, except in cases with prior mediastinal X-ray therapy,&#x000a0;then reduce the dose&#x000a0;to 400 mg/m^2. This should be used in conjunction with cytarabine.</p>
          </list-item>
          <list-item>
            <p>Patient 60 years and older:&#x000a0;30 mg/m^2 IV for one dose on days 1 to&#x000a0;2&#x000a0;for 2 cycles. Starting with the third cycle dose&#x000a0;30 mg/m^2 IV for one dose on days 1 to 3 of each cycle. The maximum cumulative dose is 550 mg/m^2, except in cases with prior mediastinal X-ray therapy, then reduce the dose&#x000a0;to 400 mg/m^2. This dosing&#x000a0;is also in conjunction with cytarabine.</p>
          </list-item>
        </list>
        <p>Renal dosing: if serum creatinine is greater than 3.0 mg/dL, the dose should be reduced by 50%.</p>
        <p>Hepatic dosing: If serum bilirubin is between 1.2 and 3.0, decrease dose by 25%; above 3.0 decrease by 50%.</p>
        <p>Always refer to institutional dosing protocols before order daunorubicin.</p>
      </sec>
      <sec id="article-20265.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Daunorubicin cause both dose-limiting and non-limiting adverse effects. Some of the common and most serious dose-limiting adverse effects include bone marrow suppression and cardiotoxicity. Bone marrow suppression usually occurs in all patients given the therapeutic dose of daunorubicin; therefore, it should be used cautiously in patients with pre-existing bone marrow suppression. It usually manifests as severe infections or hemorrhage.&#x000a0;</p>
        <p>Daunorubicin can cause potential cardiac toxicity, especially in children and the elderly. Pre-existing heart disease and concomitant treatment with other cytotoxic agents or radiotherapy involving the field of the heart can enhance the risk of developing daunorubicin-induced cardiotoxicity. It usually presents with new-onset congestive heart failure, although rarely it can present as myocarditis or pericarditis. In adults, the cardiac toxic effects are usually seen after a cumulative dose exceeding 400 to 550 mg/m^2, although it may also occur on doses as low as 200 mg/m^2.<xref ref-type="bibr" rid="article-20265.r7">[7]</xref> Symptomatic heart failure can occur during and even months to years later after the cessation of the therapy. Therefore, serial electrocardiograms (EKG) and echocardiograms are indicated before the initiation and with successive chemotherapy sessions with daunorubicin.<xref ref-type="bibr" rid="article-20265.r8">[8]</xref></p>
        <p>Other more common dose non-limiting adverse effects include reversible alopecia, mucositis, nausea, vomiting, and local skin necrosis, cellulitis, or induration due to extravasation of the drug into the tissues.</p>
        <p>Rarely it causes secondary leukemias, hypersensitivity reactions, urticaria, local dermatitis, tumor lysis syndrome, and hyperuricemia.</p>
      </sec>
      <sec id="article-20265.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>The only contraindication to the administration of daunorubicin is pre-existing hypersensitivity reactions. Though caution should be taken in patients with hepatic and renal impairment as this can increase the risk of toxicity and relative dose reduction is necessary.</p>
        <p>Daunorubicin can cross the placenta, and it can cause fetal harm when administered to pregnant women. Although no human study is available, researchers found daunorubicin to cause multiple fetal abnormalities and spontaneous abortions in reproductive animal studies. Therefore, effective contraception is the recommendation in women of reproductive age. It is not known if daunorubicin is secreted in breast milk or not, but due to the potential harm, breastfeeding is generally not recommended during the ongoing therapy.</p>
      </sec>
      <sec id="article-20265.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Therapy with daunorubicin generally requires close patient observation and follow-ups. Serial measurement of complete blood count, hepatic, and renal functions is recommended before each chemotherapeutic session. Monitoring for bone marrow suppression and infections requires care and vigilance, and any systemic infection should be treated effectively before the next course of daunorubicin.</p>
        <p>The American College of Clinical Oncology (ASCO) recommends cardiac monitoring, including a thorough history and physical exam, screening for cardiovascular risk factors, EKGs, and serial echocardiograms. For patients who become symptomatic, the initial diagnostic test should be transthoracic echocardiography (echo). If the echo is inconclusive, a cardiac MRI or MUGA scan is an alternative. It is also a recommendation to obtain cardiac markers if necessary.<xref ref-type="bibr" rid="article-20265.r8">[8]</xref></p>
      </sec>
      <sec id="article-20265.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Daunorubicin causes cardiotoxicity by forming complexes with topoisomerase IIb enzyme in cardiomyocytes. This activity&#x000a0;is the same as when the drug forms complexes with topoisomerase IIa in tumor cells and can result in mitochondrial damage&#x000a0;with subsequent myocardial cell death. Dexrazoxane is a cardio-protectant agent. Research has shown it to decrease the incidence and severity of cardiotoxicity when given from the first dose of anthracyclines without reducing the effectiveness of the chemotherapeutic agent. It acts by inhibiting the isomer of topoisomerase and decrease the free radical damage by chelating free iron.<xref ref-type="bibr" rid="article-20265.r7">[7]</xref><xref ref-type="bibr" rid="article-20265.r9">[9]</xref>&#x000a0;It is administered intravenously in a ratio of 10&#x000a0;to 1 of dexrazoxane: daunorubicin. Cardiac monitoring is still a recommendation despite concurrent therapy, and if a patient develops a decline in the left ventricular function or develops symptomatic heart failure, treatment should discontinue immediately.</p>
      </sec>
      <sec id="article-20265.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Due to the serious toxic effects of daunorubicin therapy, strong interprofessional communication and care coordination are recommended among oncologists, family clinicians (MDs, DOs, NPs, PAs), nurses, and pharmacists. Administration of the drug should only be by a team trained in leukemia chemotherapy and centers with training on monitoring drug tolerance, toxic monitoring, and surveillance. There should also be effective resources available to treat any adverse effects related to daunorubicin therapy especially acute fatal infections or severe hemorrhage related to bone marrow suppression and decompensations due to acute congestive heart; in that case, cardiology referral is immediately necessary.&#x000a0;</p>
        <p>Dexarozoxane is recommended to prevent the cardiotoxic effects of daunorubicin and has shown effective results in large randomized clinical trials.<xref ref-type="bibr" rid="article-20265.r9">[9]</xref></p>
      </sec>
      <sec id="article-20265.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20265&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20265">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20265/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20265">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20265.s11">
        <title>References</title>
        <ref id="article-20265.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wei</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Gale</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zhou</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Qiu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Randomized Trial of Intermediate-dose Cytarabine in Induction and Consolidation Therapy in Adults with Acute Myeloid Leukemia.</article-title>
            <source>Clin Cancer Res</source>
            <year>2020</year>
            <month>Jul</month>
            <day>01</day>
            <volume>26</volume>
            <issue>13</issue>
            <fpage>3154</fpage>
            <page-range>3154-3161</page-range>
            <pub-id pub-id-type="pmid">32029439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pophali</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Litzow</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?</article-title>
            <source>Curr Treat Options Oncol</source>
            <year>2017</year>
            <month>Jan</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <pub-id pub-id-type="pmid">28154969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perl</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>The role of targeted therapy in the management of patients with AML.</article-title>
            <source>Hematology Am Soc Hematol Educ Program</source>
            <year>2017</year>
            <month>Dec</month>
            <day>08</day>
            <volume>2017</volume>
            <issue>1</issue>
            <fpage>54</fpage>
            <page-range>54-65</page-range>
            <pub-id pub-id-type="pmid">29222237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mehta-Shah</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ratner</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Horwitz</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Adult T-Cell Leukemia/Lymphoma.</article-title>
            <source>J Oncol Pract</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>487</fpage>
            <page-range>487-492</page-range>
            <pub-id pub-id-type="pmid">28796966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maakaron</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Mims</surname>
                <given-names>AS</given-names>
              </name>
            </person-group>
            <article-title>Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.</article-title>
            <source>Best Pract Res Clin Haematol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>32</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-133</page-range>
            <pub-id pub-id-type="pmid">31203994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Petre</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Dittmer</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Liposomal daunorubicin as treatment for Kaposi's sarcoma.</article-title>
            <source>Int J Nanomedicine</source>
            <year>2007</year>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>277</fpage>
            <page-range>277-88</page-range>
            <pub-id pub-id-type="pmid">18019828</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chang</surname>
                <given-names>VY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JJ</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenetics of Chemotherapy-Induced Cardiotoxicity.</article-title>
            <source>Curr Oncol Rep</source>
            <year>2018</year>
            <month>Apr</month>
            <day>30</day>
            <volume>20</volume>
            <issue>7</issue>
            <fpage>52</fpage>
            <pub-id pub-id-type="pmid">29713898</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armenian</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Lacchetti</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Barac</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Carver</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Constine</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Denduluri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Dent</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Douglas</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Durand</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Ewer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fabian</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hudson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jessup</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>LW</given-names>
              </name>
              <name>
                <surname>Ky</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Mayer</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Moslehi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Oeffinger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ray</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ruddy</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Lenihan</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Mar</month>
            <day>10</day>
            <volume>35</volume>
            <issue>8</issue>
            <fpage>893</fpage>
            <page-range>893-911</page-range>
            <pub-id pub-id-type="pmid">27918725</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20265.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marty</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Espi&#x000e9;</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Llombart</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Monnier</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rapoport</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Stahalova</surname>
                <given-names>V</given-names>
              </name>
              <collab>Dexrazoxane Study Group</collab>
            </person-group>
            <article-title>Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy.</article-title>
            <source>Ann Oncol</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>614</fpage>
            <page-range>614-22</page-range>
            <pub-id pub-id-type="pmid">16423847</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
